Zacks Investment Research upgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a sell rating to a hold rating in a research report sent to investors on Monday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the subject of a number of other reports. BidaskClub cut DBV TECHNOLOGIE/S from a hold rating to a sell rating in a research note on Thursday, October 11th. Bank of America lowered their target price on DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a buy rating for the company in a research note on Friday, November 2nd. Stifel Nicolaus started coverage on DBV TECHNOLOGIE/S in a research note on Thursday, September 13th. They set a buy rating and a $35.00 target price for the company. Finally, Morgan Stanley lowered their target price on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an equal weight rating for the company in a research note on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. DBV TECHNOLOGIE/S currently has an average rating of Hold and an average price target of $33.67.
NASDAQ DBVT opened at $14.76 on Monday. DBV TECHNOLOGIE/S has a 52-week low of $13.51 and a 52-week high of $26.98. The company has a market cap of $870.37 million, a P/E ratio of -4.38 and a beta of 1.19.
Institutional investors and hedge funds have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter worth approximately $285,000. Exane Asset Management grew its stake in shares of DBV TECHNOLOGIE/S by 17.9% during the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock worth $964,000 after acquiring an additional 7,600 shares in the last quarter. Bailard Inc. grew its stake in shares of DBV TECHNOLOGIE/S by 57.4% during the 3rd quarter. Bailard Inc. now owns 74,000 shares of the company’s stock worth $1,662,000 after acquiring an additional 27,000 shares in the last quarter. First Midwest Bank Trust Division grew its stake in shares of DBV TECHNOLOGIE/S by 19.3% during the 3rd quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock worth $3,669,000 after acquiring an additional 26,372 shares in the last quarter. Finally, BlackRock Inc. grew its stake in shares of DBV TECHNOLOGIE/S by 4.7% during the 2nd quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock worth $5,970,000 after acquiring an additional 14,032 shares in the last quarter. 45.43% of the stock is owned by institutional investors.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: What are the benefits of a balanced fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.